




Prostate cancer is the most common malig-
nancy and the second leading cause of cancer-
related death in men in the United States. Cur-
rent therapeutics for advanced human prostate 
cancer is limited by the propensity of the dis-
ease to progress from an androgen-dependent 
to an androgen-independent phenotype. Anti-
cancer therapeutic approaches such as ionizing 
radiation can activate cellular apoptotic machin-
ery in androgen-independent prostate cancer 
cells [1-3]. However, acquired radiation resis-
tance is developed in hormone-refractory pros-
tate cancer that is associated with apoptosis-
resistance [4, 5]. Therefore, apoptosis tends to 
be involved in the molecular mechanism of ra-
diosensitivity in prostatic tumors [6]. Indeed, 
defects in the apoptosis machinery have been 
connected to the resistance of cancer cells to 
current therapeutic interventions including ion-
izing radiation [7, 8].     
 
Growing evidences have shown that acquired 
resistance to radiation therapy can be overcome 
by utilizing small-molecule compounds that tar-
get key proteins involved in radiation resistance 
[9]. The mechanism of drug-mediated radiosen-
sitization can be categorized into several modes 
[10], in which cell cycle redistribution is demon-
strated as one of the crucial mechanisms. As 
differential response of the cells to radiation 
depends on the cell cycle phases, an agent that 
can synchronize tumor cells in a phase of the 
cell cycle that is sensitive to radiation is sup-
posed to be a potential therapeutic candidate 
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Abstract:  Embelin is an active ingredient of traditional herbal medicine that exhibits anti-tumor effects in human 
prostate cancer cells. However, therapeutic effect of embelin in combination with conventional radiation therapy is 
not yet determined. In this study, we evaluate the sensitizing potential of embelin on ionizing radiation (IR) in a hu-
man prostate cancer model. In vitro, embelin combined with radiation potently suppressed prostate cancer PC-3 cell 
proliferation that was associated with S and G2/M arrest in cell cycle. Moreover, the combination treatment pro-
moted caspase-independent apoptosis, as evidenced by the increased apoptotic cell death without caspase-3 activa-
tion, but not autophagy. Clonogenic survival assay showed that S-phase arrest was required for embelin-mediated 
radiosensitization. In vivo, embelin significantly improved tumor response to X-ray radiation in the PC-3 xenograft 
model. Combination therapy produced enhanced tumor growth delay and prolonged time to progression, with mini-
mal systemic toxicity. Immunohistochemistry studies showed that embelin plus IR significantly inhibited cell prolifera-
tion, induced apoptosis, and decreased microvessel density in tumors as compared with either treatment alone, sug-
gesting an enhanced combinatory inhibition on tumor suppression and angiogenesis. Our results demonstrate that 
embelin significantly facilitates tumor suppression by radiation therapy both in vitro and in vivo in the prostate cancer 
model. This finding warrants embelin as a novel adjuvant therapeutic candidate for the treatment of hormone-
refractory prostate cancer that is resistant to radiation therapy.  
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for facilitating radiotherapy efficacy [11, 12]. As 
such, it is not surprising that apoptosis may be 
involved as a mechanism for drug-mediated 
radiosensitization, if the radiosensitivity de-
pends on cell cycle progression [11].  
 
Radiation-produced apoptosis is an active cellu-
lar response that is considered to be a cell fate 
when cells fail to recover from DNA damage 
repair and cell cycle arrest [13-15]. Although 
controversial in some circumstances, the rela-
tionship between apoptosis and radiosensitivity 
is widely documented [16, 17]. We have previ-
ously reported that (-)-gossypol, a natural Bcl-2 
inhibitor, enhances tumor regression by radio-
therapy in a prostate cancer model in vivo [6, 
18]. Furthermore, in vitro, (-)-gossypol combined 
with radiation synergistically triggers apoptosis 
in a schedule-dependent manner [6]. In another 
study, a synthetic small molecule XIAP inhibitor 
shows radiosensitizing effect by facilitating ra-
diation-induced apoptosis in the hormone-
refractory prostate cancer [19, 20]. These stud-
ies provide evidences that in prostate cancer, 
apoptosis could be a consequential outcome for 
combining radiation with antagonists of anti-
apoptotic proteins.   
 
Embelin is an active ingredient of traditional 
herbal medicine for cancer and other diseases 
[21]. We have previously identified embelin as a 
potent inhibitor of X-linked inhibitor of apoptosis 
protein (XIAP), making embelin the first reported 
natural small molecule XIAP-inhibitor [22].  Be-
sides its antibacterial activity, embelin exhibits 
cytotoxic effect and inhibits cell proliferation in 
various cancer cell types [22-26], presumably 
by activating apoptosis machinery [22, 25, 27]. 
Furthermore, embelin is reported to enhance 
tumor cell apoptosis induced by tumor necrosis 
factor alpha (TNFa) [21] or TNF-related apop-
tosis-inducing ligand (TRAIL) [28, 29], suggest-
ing that embelin can be applied in conjunction 
with other therapeutic modalities for cancer 
therapy. However, so far there is no report on 
combining embelin with radiotherapy for human 
cancer treatment.  
 
In this study, we aim to evaluate the effect of 
embelin on prostate cancer radiosensitivity. We 
investigate the combinatorial efficacy of embe-
lin and ionizing radiation both in vitro and in vivo 
in a preclinical prostate cancer model. We also 
explore the underlying mechanism of embelin-
mediated radiosensitization.  
Materials and methods 
 
Reagents and cell culture 
 
Embelin (98%) was purchased from INDOFINE 
Chemical Company (Hillsborough, NJ). The pow-
der was reconstituted in dimethyl sulfoxide 
(DMSO) and stored as aliquots (50 mM) at -70°
C. Fluorogenic substrates DEVD-AFC and Stauro-
sporin were purchased from BioVision 
(Mountain View, CA). Anti-poly(ADP-ribose) poly-
merase (PARP) (F-2) antibody was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-XIAP antibody was purchased from BD Bio-
sciences (San Jose, CA). Anti-β-actin (AC-74) 
antibody was obtained from Sigma (St. Louis, 
MO). Protease inhibitor cocktail was from Roche 
(Indianapolis, IN). Other chemicals were from 
Sigma unless otherwise indicated. Human pros-
tate cancer cell lines PC-3 and DU-145 were 
purchased from American Type Culture Collec-
tion. Cells were maintained in RPMI 1640 sup-
plemented with 10% FBS, 100 U/ml penicillin, 
and 100 μg/ml streptomycin, and incubated in 
a 5% CO2 humidified incubator at 37°C. All tis-
sue culture reagents were purchased from Invi-
trogen (Grand Island, NY). 
 
Cell proliferation and cell death assays 
 
The cell proliferation was assessed by cell 
counting [18, 30, 31]. Briefly, cells were seeded 
in a 24-well plate at a density of 2x105 cells/
well and treated with embelin, IR or in combina-
tion in triplicate. Every 24 h for up to 7 days, 
attached cells were harvested and counted us-
ing a Coulter cell counter (Fullerton, CA). Rela-
tive cell number was normalized by dividing cell 
number at various times to the average number 
of untreated control on the first day (day 0). For 
cell death analysis, total cells (including both 
floating and attached cells) were harvested and 
stained with trypan blue [32, 33]. Percentage of 
cell viability was calculated by dividing the num-
ber of negative-stained cells to total cells. Data 
were from two independent samples in tripli-
cate. Data were plotted and analyzed by Graph-
Pad Prism 5.0 (San Diego, CA). Autophagy as-
says were carried out as we described recently 




Annexin V binding assay was employed to de-
tect apoptosis, using an Annexin V-FITC and 
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propidium iodide (PI) staining kit (Roche) ac-
cording to the manufacturer’s instruction. Cells 
in the lower right quadrant were scored as 
“early apoptosis” [Annexin (+) /PI (-)], and in the 
upper right quadrant were scored as “necrosis/
late apoptosis” [Annexin (+)/PI (+)] [18, 35]. For 
cell cycle and sub-G1 analysis, the harvested 
cells were fixed in 70% ethanol at 4oC overnight, 
then treated with propidium iodide (PI, 50 μg/
ml) and RNase A (1 μg/ml) for 30 min. Samples 
were analyzed by flow cytometry (FACSCalibur, 
BD Biosciences). sub-G1 population was calcu-
lated from hypodiploid DNA fluorescent in the 
cell cycle histogram [18, 30, 36]. Data were 
analyzed using WinMDI 2.8 software (Purdue 
University Cytometry Laboratory). 
 
Caspase activation assay 
 
Cells were resolved in a lysis buffer (BioVision), 
and whole cell lysates (40 μg) were incubated 
with 20 μM of fluorogenic substrate DEVD-AFC 
in a reaction buffer (BioVision) containing 5 mM 
DTT at 37oC for 1 h. Proteolytic release of AFC 
was monitored at λex = 405 nm and λem = 500 
nm using a fluorescence microplate reader 
(BMG, Cary, NC). Fold increase of fluorescence 
signal was calculated by comparing the normal-
ized signal in each treated sample with that in 
the untreated control [30, 35].  
 
Western blot analysis 
 
Western blot was carried out as described previ-
ously [30, 32, 37]. For xenografted tumor tis-
sue, a homogenizer (Fisher) was used. Total 
protein extraction was quantified using the 
Bradford reagent (Bio-Rad, Hercules, CA). Whole 
cell lysates were resolved by SDS-PAGE (Bio-
Rad), electrotransferred to nitrocellulose mem-
branes (Bio-Rad) and probed with respective 
antibodies.  
 
Clonogenic cell survival assay 
 
Cells were pretreated with various doses of Em 
for a desired time course and irradiated by X-ray 
as described [9, 19]. Cells were then seeded in 
6-well plates at the desired cell density 
(200~10,000 cells/well) based on treatment 
stringency in the absence of embelin. After 12-
14 days incubation, plates were stained with 
crystal violet (0.1%). Colonies over 50 cells were 
manually counted. The survival curves were 
plotted using a standard linear-quadratic model 
[35, 38]. Triplicated data of each sample were 
normalized and the enhancement ratio (ER) was 




Female athymic NCr-nu/nu mice (5~6 weeks) 
were inoculated subcutaneously (s.c.) on both 
sides of the lower back above the tail with 
3×106 cells/0.2 ml of PC-3 cells [9]. When tu-
mors reached around 100 mm3, the mice were 
randomized into 4 groups with 8~10 mice per 
group and treated daily with (a) vehicle control 
[0.1% carboxymethyl cellulose (CMC)]; (b) X-ray 
radiation at 2 Gy fraction on days 1 to 5 weekly 
for 2 weeks; (c) embelin via oral gavage (p.o) at 
a dose of 60 mg/kg on days 1 to 5 weekly for 3 
weeks; and (d) X-ray radiation plus embelin. 
Embelin was dosed 1 h before irradiation. Tu-
mor size and body weight were measured twice 
a week using a venier caliper. Tumor volume 
was calculated using the formula: (length × 
width2)/2. Tumor doubling time was evaluated 
by monitoring the first day when the tumor vol-
ume was twice baseline volume, and character-
ized by Kaplan-Meier estimate [9, 18, 30, 35]. 
All the experiments were done according to the 
protocols approved by University of Michigan 




Tumor samples were fixed in 4% paraformalde-
hyde at 4 oC overnight for paraffin embedding. 
Other than hematoxylin and eosin (H&E) stain-
ing, cell proliferation was tested by Ki-67 and 
proliferating cell nuclear antigen (PCNA) stain-
ing, apoptosis was detected by Terminal de-
oxynucleotidyl Transferase Biotin-dUTP Nick End 
Labeling (TUNEL) staining using an in situ Apop-
Tag kit, and tumor angiogenesis was analyzed 
by anti-mouse CD31 staining for detection of 




Two-tailed Student’s t-test was employed for 
analyzing both in vitro and in vivo data. Two-way 
ANOVA was applied to analyze tumor growth. 
Mantel-Cox (Log-Rank) test was used for sur-
vival analysis. All analysis was performed by 
GraphPad Prism 5.0. A threshold of P < 0.05 




Embelin combined with IR inhibits cell growth 
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and induces cell death 
 
We have previously reported embelin inhibits 
prostate cancer cell growth in vitro [22]. Previ-
ous reports have shown that small-molecule 
treatments may help sensitize cancer cells to 
radiation therapy [9].  To investigate if embelin 
could work in this manner, we first wanted to 
monitor if it had any effects on cell proliferation 
and cell death.  We used the human prostate 
cancer PC-3 cells.  Here, we confirm that embe-
lin alone dose-dependently inhibited PC-3 cell 
growth (Figure 1A) and induced PC-3 cell death 
(Figure 1B and Table 1). From day 5 post-
treatment, 10 μM of embelin exerted significant 
growth control (>45%), whereas 20 μM of em-
belin showed drastic cell-killing effect (>60%). 
These data suggest that embelin is a cytostatic 
rather than cytotoxic agent since it favors sup-
pressing cell proliferation, with observed cyto-
toxicity only at higher doses and a longer expo-
Figure 1. Effect of embelin (Em) combined with IR on PC-3 
cell proliferation and cell death. A, Em alone or combined 
with IR inhibited cell growth. PC-3 cells were treated with 10 
μM and 20 μM of Em, 4 Gy irradiation, or in combination. 
Em remained continuous exposure to the cells throughout 
the experiments. Attached cells were harvested and 
counted every day for 7 days. Data are expressed as the 
ratio of cell number with treatment to the untreated control. 
Data shown are means ± SD (n=6). B, Em alone or com-
bined with IR promoted cell death. Both attached and float-
ing cells were harvested for trypan blue staining. Cell viabil-
ity (%) was quantified by dividing the number of unstained 
cells to total cells. Data shown are means ± SD (n=6). C, cell 
density was monitored 72 h after treatment. Typical pictures 




Table 1.  Effect of embelin with IR on PC3 cell 
growth and cell death 
Treatment Cell growth 
inhibition (%) 
Cell death (%) 
DMSO   0.00 ± 1.41   1.72 ± 0.60 
Em (10 μM) 25.18 ± 4.62   2.73 ± 1.27 
Em (20 μM) 54.28 ± 0.94   6.80 ± 2.02 
IR (4 Gy) 39.80 ± 4.77   6.13 ± 1.03 
Em (20 μM) 
+ IR (4 Gy) 
72.17 ± 
3.56*** 
14.19 ± 2.94* 
Note:  At 72 h after treatment, cell growth inhibition (%) 
and cell death (%) were calculated based on relative cell 
number (Figure 1A) and  viability (Figure 1B), respec-
tively. Data are shown as mean ± SD (n=6) *, P< 0.05; 
***, P< 0.001 vs. IR or Em alone. 
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sure time. Moreover, embelin plus IR achieved 
significantly more cell growth inhibition 
(P<0.001) and cell death (P<0.05) as compared 
with either treatment alone after day 2 (Figure 1 
and Table 1). These data suggest that embelin 
in combination with ionizing radiation potently 
reduced cancer cell proliferation as well as en-
hanced cancer cell death.   
Figure 2. Cell cycle analysis of PC-3 after Em and IR treatment. A, cells were treated with Em (20 μM), IR (4 Gy) or in 
combination for 24 h and 72 h, respectively. Data represent one of three independent experiments. B, cell population 
(%) in each phase was quantified. Columns, mean of three independent experiments; bars, SD (n=3). *, P< 0.05.  
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Embelin combined with IR induces cell cycle 
arrest 
 
As embelin plus IR exhibited potent anti-
proliferation effect in vitro, we further tested the 
cell cycle distribution in the treated cells. While 
IR induced G2/M arrest, embelin alone trig-
gered S-phase arrest dose-dependently (Figure 
2A and Figure 3A). After 72 h, S-phase cell 
population showed 2.1±0.8 folds at 10 μM and 
3.6±1.1 folds at 20 μM, respectively. In addi-
tion, embelin plus IR induced both S and G2/M 
arrest comparing with control (P<0.05) (Figure 
2B). This result suggests that embelin alone, as 
well as combined with IR, induced cell cycle 
arrest in PC-3 cells.   
Embelin combined with IR triggers caspase-
independent apoptosis 
 
As mentioned above, embelin alone or plus IR 
exhibited cytotoxic effect (Figure 1B). We then 
determined whether apoptosis is involved in 
such cytotoxicity. Embelin plus IR induced sig-
nificantly more hypodiploid sub-G1 population 
than either treatment alone (P<0.05), consis-
tent with the known apoptosis-inducer stauro-
sporin (Figure 4A). However, the combination 
treatment barely increased the Annexin V+ PI- 
apoptotic cell population (Figure 4B). Instead, 
Annexin V+ PI+ population was enhanced by the 
combination treatment when compared with 
either treatment alone (Figure 4B), suggesting 
Figure 3. Dose effect of Em on radiosensitization. A, Em induced S phase arrest in PC-3 dose-dependently. Cells were 
treated with various doses of Em for 72 h. Cell cycle was analyzed and cell population in each phase is numerically 
depicted. Gemcitabine (Gem) (Lilly, Indianapolis, Indiana) was used as a positive control, treating cells at a dose of 1 
μM for 24 h. Data represent one of two independent experiments. B, clonogenic survival curve of cells pretreated 
with indicated dose of Em, as described in A. Data are shown as mean ± SD (n=3). C, clonogenic survival curve of 
cells pretreated with 1 μM and 2 μM of Gem for 24 h.  Data are shown as mean ± SD (n=3). 
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the activation of late apoptosis. Interestingly, 
neither single nor combined treatment triggered 
caspase-3 activation (Figure 4C) and PARP 
cleavage (Figure 4D), which was in contrast with 
staurosporin that induced caspase-dependent 
apoptosis. We have also carried out autophagy 
analysis and found that embelin did not induce 
significant autophagy in the conditions tested 
(Figure 5). Furthermore, neither treatment de-
creases expression of multiple anti-apoptotic 
proteins including Bcl-2, Bcl-xL, XIAP and cIAP-1, 
but not Mcl-1, (Figure 6).  These data demon-
strate that embelin combined with IR augments 
cell apoptosis that is caspase-independent.  
 
Embelin radiosensitizes PC-3 cells via cell cycle 
arrest at S-phase 
 
We next evaluated radiosensitization potential 
of embelin in prostate cancer cells. We per-
formed series of clonogenic assays using differ-
ent schedules to assess the therapeutic effects.  
The PC-3 cells offered an outstanding opportu-
nity to study this because of the ideal size and 
morphology of its formed colonies and relative 
plating efficiency when treated with embelin 
(Figure 7A and C).  Colony formation assay 
showed that embelin alone minimally inhibited 
PC-3 colony growth below 10 mM (Figure 7A), 
thus a concentration of 10 mM was used for 
later experiments. After pretreatment for 48 h, 
embelin sensitized radiation-induced clonogenic 
cell growth inhibition in a dose-dependent mode 
(Figure 3B), similar to the well-documented ra-
diosensitizer gemcitabine that also induces S 
arrest (Figure 3C).  
 
We have shown that embelin alone induces S-
phase arrest and exerts enhanced apoptosis 
when combined with IR. We also evaluated 
whether S arrest is correlated with radiosensitiv-
ity by embelin. With increased pretreatment 
Figure 4. Combination effect of Em and IR on cell death in vitro. A, PC-3 cells were treated with Em (20 μM), IR (4 Gy) 
or in combination for 72 h. Cells treated with staurosporin (STS, 1 μM) for 24 h was used as a positive control. Sub-
G1 cell population was the hypodiploid DNA contents from the cell cycle diagram by flow cytometry analysis. Columns, 
mean of two independent experiments; bars, SD (n=2). *, P< 0.05. B, cells were treated with Em (20 μM), IR (4 Gy) or 
in combination for 48 h, or with STS (1 μM) for 4 h. Cells were stained with Annexin V and PI and analyzed by flow 
cytometry. Cell population in each indicated quadrant is numerically depicted. Data represent one of two independent 
experiments. C, cells were treated as described in A, and enzymatic activity of caspase-3 was determined by fluores-
cence. The activity of the control was defined as “1”. Columns, mean; bars, SD (n=3). D, cells were treated as de-
scribed in A. Whole cell lysates (50 μg) were analyzed by Western blot and visualized by anti-PARP antibody. Actin is 
used as a loading control.  
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Figure 5. Embelin does not induce autophagy in prostate cancer cells. A,  The cells were treated with 5, 10 and 20μM 
Embelin or DMSO for 16h, then stained with acridine orange. Quantitative data was shown as percent of cells with 
orange punctuates punctuate (n=5).  B,  Cells were transfected by LC3-GFP plasmid, treated with 5, 10 and 20μM 
Embelin or DMSO for 24h, and then analyzed under a fluorescent microscope. Quantitative data was shown as per-
cent of cells with punctuate LC3-GFP (200 cells, n=5). 
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time, embelin facilitated IR-induced clonogenic 
cell growth inhibition, as per enhancement ratio 
(Figure 7B). When cells were pretreated with 
embelin for 72 h, maximum effect was ob-
served even at a lower IR dose of 2 Gy (Figure 
7B and C). The results demonstrate that embe-
lin radiosensitizes PC-3 cells in a dose- and time
-dependent manner, and is correlated with em-
belin-induced S-phase arrest. To explore 
whether radiation-induced DNA repair is in-
volved in embelin-mediated radiosensitization, 
we compared two different treatment sched-
ules. Cells pretreated with embelin for 1 h be-
fore radiation followed by 24 h post-radiation 
showed less clonogenic survival compared with 
72 h pretreatment before radiation (P<0.01, 
Figure 7D), suggesting that cell cycle arrest, but 
not DNA repair, is a major mechanism involved 
in embelin-mediated radiosensitization. This is 
further confirmed by the immunostaining of nu-
clear gH2AX that embelin indeed hardly im-
paired IR-induced DNA damage repair (Figure 
8). Overall, these results indicate that embelin 
sensitizes PC-3 cells to X-ray radiation is associ-
ated with the S-phase arrest.   
 
Embelin potentiates IR-induced tumor regres-
sion in PC-3 xenografts 
 
To evaluate the radiosensitization potential of 
embelin in vivo, we employed the PC-3 xeno-
graft tumor model as we previously described 
[9]. As shown in Figure 9A, the combination 
therapy inhibited tumor growth more potently 
than either treatment alone (P< 0.001, Two-way 
ANOVA). At the end of treatment (day 18), me-
dian tumor size in the combination group was 
60% of that in IR alone group (P< 0.001), and 
18% of that in control group (P<0.001) (Figure 
9B). Notably, the mice body weight loss was less 
than 15% during the treatment, and rapidly re-
covered right after the cessation of treatment, 
suggesting that the accumulated systemic toxic-
ity by the treatment is transient and reversible 
(Figure 9C). When monitoring tumor growth of 
each mouse throughout the experiment, the 
combination treatment significantly increased 
tumor-doubling time, 5~6-folds longer than ei-
ther treatment alone (P<0.001 by Mantel-Cox) 
(Figure 9D), indicating an improvement of the 
overall survival. Together, these data demon-
strate that embelin plus IR resulted in prostate 
tumor growth inhibition and prolonged survival 
with minor systemic toxicity.   
 
Embelin combined with IR reduces cell prolif-
eration and angiogenesis, and induces apop-
tosis in vivo 
 
To further confirm the anti-tumor efficacy by 
combination treatment, tumor samples were 
processed for both histological and biological 
analyses. Embelin plus IR group showed fewer 
Ki67- and PCNA-positive cells, more TUNEL-
positive cells and fewer CD31-positive microves-
sels than either treatment alone (Figure 10A). 
Such difference was significant after quantifica-
tion between combination and IR alone group 
(P<0.001 for Ki67 and PCNA; P<0.05 for TUNEL 
and CD31) (Figure 10B). Consistent with TUNEL 
staining, the combination group, but not single 
treatments, induced PARP cleavage in the tu-
mor tissue (Figure 10C). Moreover, embelin plus 
IR dramatically decreased XIAP expression than 
either embelin or IR alone (Figure 10C). These 
data demonstrate that combining embelin with 
radiation potently suppresses proliferation, trig-
gers apoptosis and reduces angiogenesis in 




In this study, we found that embelin enhances 
therapeutic efficacy of radiation therapy in hu-
man prostate cancer PC-3 both in vitro and in 
Figure 6.  Expression of anti-apoptotic proteins after 
Em and IR treatment in vitro. Samples in Figure 3D 
were probed with antibodies against Bcl-2 (Santa 
Cruz), Bcl-xL (BD), Mcl-1 (Santa Cruz), XIAP (BD) and 
cIAP-1 (Santa Cruz).  
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vivo. Embelin combined with X-ray radiation 
achieved increased tumor growth inhibition and 
apoptosis, which is accompanied by the embe-
lin-induced cell cycle arrest in S-phase. More-
over, the combination treatment increased cas-
pase-independent apoptosis but not autophagy. 
Clonogenic survival assay showed that S-phase 
arrest was required and may serve as a major 
mechanism for embelin-mediated radiosensiti-
zation. In vivo, embelin significantly enhanced 
tumor growth inhibition and time to progression 
by radiation therapy in PC-3 xenografts with 
minimal systemic toxicity. Immunohistochemis-
try studies displayed that embelin plus IR signifi-
cantly inhibited cell proliferation and microves-
sel density, and induced apoptosis in tumors as 
compared with either treatment alone. To-
gether, these data demonstrate the tangible 
effect of embelin in combination with radiation 
and provide a potential mechanism of embelin-
mediated radiosensitization. To our knowledge, 
this is the first report on the combinational ap-
plication of embelin with ionizing radiation for 
human cancer therapy. 
 
Embelin was identified as the first natural XIAP 
antagonist by our group and collaborators [22], 
together with series of related compounds and 
Figure 7. Radiosensitization effect of Em. A, PC-3 cells (200 cell/well) were treated with indicated dose of Em for 72 h 
and incubated in the fresh medium without Em for another 11 days. Plating efficiency is expressed as a percentage 
of colonies in treated group by untreated control. Bars, SD (n=3). B, cells were pretreated with 10 μM of Em for 24 h, 
48 h, and 72 h, respectively, and irradiated. Cells were then seeded at desired densities according to different doses 
of IR without Em. The survival curves were plotted using a standard linear-quadratic model. ER, enhancement ratio. 
Bars, SD (n=3). Data represent one of three independent experiments. C, stained colonies in a typical well by the 
treatment in B are shown. D, cells were exposed to Em and IR with two different sequences. Em-IR-DMSO: cells were 
pretreated with 10 μM of Em for 72 h and irradiated. Right after radiation, cells were seeded for clonogenic assay 
without Em (with DMSO control). Em-IR-Em: cells were pretreated with 10 μM of Em for 1 h and irradiated. Cells were 
incubated with Em (10 μM) for another 24 h post-irradation and seeded. Clonogenic survival analysis was performed 
as described in B. Bars, SD (n=3). Data represent one of two independent experiments.  
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derivatives [20, 39, 40]. Since XIAP blocks 
apoptosis by neutralizing caspase activity [41, 
42], it is not surprising that embelin exerts pro-
apoptotic effect in various cancer cell types [22, 
23, 27]. However in our study, a single use of 
embelin is not sufficient to induce apoptosis, 
although dramatic growth inhibition is observed. 
This result suggests that embelin functions as a 
cytostatic instead of cytotoxic agent that halts 
cell proliferation without inducing apoptosis or 
autophagy. We have previously shown that em-
belin potently induced apoptosis in DU-145 
cells, another prostate cancer cell line [22]. 
 
Albeit its less apoptotic-inducing effect alone, 
embelin can potentiate radiation therapy, as 
evidenced by the results that embelin was able 
to enhance the tumor regression by ionizing 
radiation in the PC-3 model. Interestingly, we 
find that in vitro, the combination treatment 
leads to enhanced apoptosis that is not corre-
lated with caspase-3 activation, suggesting that 
apoptosis is caspase-independent; while in vivo 
in tumor tissues, the combination therapy in-
deed triggers caspase-dependent apoptosis. 
Moreover, XIAP expression is reduced in tumors 
while remains unchanged in cells with either 
treatment, suggesting that XIAP may likely be 
interfered only in the presence of tumor micro-
environment. This postulation is further con-
firmed by the fact that intratumoral angiogene-
sis is reduced along with augmented apoptosis. 
The discrepancy of the mode of cell death be-
tween the in vitro and in vivo setting remains 
unclear. Nevertheless, the growth inhibition is 
consistent in cells and in animal model, demon-
strating the anti-tumor efficacy generated by 
embelin plus IR. 
 
Combination of radiation and other agents that 
achieve radiosensitizing potential has become 
important interventions for the patients with 
solid tumors, including the locally advanced, 
castration resistant prostate cancer [43]. De-
spite the fact that cells in G2/M phase are the 
most sensitive to radiation, S-phase arrest is 
indispensable for drug-mediated radiosensitiza-
tion in some combination treatments, although 
the S-phase cells are supposed to be relatively 
resistant to radiation [11]. For example, it is well 
documented that gemcitabine-mediated radio-
sensitization is dependent on S-phase arrest 
induced by the drug, and such finding implies 
the importance of both depletion of phosphory-
lated deoxynucleotides and redistribution of 
cells through S-phase [44]. Also, radiosensitiza-
tion effect of 5-fluorouracil (5-FU) is only 
achieved when 5-FU is present before radiation, 
suggesting that S-phase arrest is necessary for 
its radiosensitivity [45]. These evidence demon-
strate that the improvement of radiotherapy 
combinations with a proper scheduling will help 
to rationally develop new radiosensitizing strate-
gies. 
 
Consistent with the behaviors of those chemo-
therapeutic agents, our study shows that embe-
lin-induced S-phase arrest seems to play a role 
in its radiosensitizing activity, suggesting that 
embelin may function as an S-phase radiosensi-
Figure 8. Em hardly impaired IR-induced DNA damage 
repair. Immunostaining of nuclear gH2AX was con-
ducted as described previously [9]. gH2AX foci are 
shown as green fluorescent dots counterstained with 
DAPI. Original magnification, x400. Fifty cells were 
selected randomly for foci quantification (x400). Data 
are shown as mean ± SD (n=50).   
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tizer. Also, the dependence of S-phase progres-
sion for radiosensitizing potential and acquired 
apoptosis by embelin precludes a functional 
role of p53, as suggested in other studies [46]. 
Our data also reveal that cell cycle modulation 
but not DNA damage repair seems to be a pre-
dominant mechanism involved in embelin-
mediated radiosensitization. Moreover, en-
hanced apoptosis by combination therapy is 
less likely to be a consequence of radiosensiti-
zation as the schedule of apoptosis and clono-
genic survival is different. Overall, these two 
independent outcomes support the therapeutic 
potential of combining embelin and radiation 
therapy. In addition, it is worth noting that em-
belin seems to induce S---phase arrest only in 
PC-3 cells but not in other cancer cells (data not 
shown and ref. [23]), indicating that the effect 
of cell cycle redistribution by embelin is cellular 
context-dependent. As such, our finding at least 
Figure 9. Combinatorial effect of Em and IR on PC-3 xenograft. Nude mice bearing PC-3 tumors were treated with Em, 
IR, or in combination, as described in Materials and Methods. A, PC-3 tumor growth curve with desired treatments. 
Data are shown as mean ± SEM (n  14). ***, P<0.001 vs. IR (two-way ANOVA). B, tumor suppression (T/C) was 
calculated as the ratio of the median tumor volume in the treated group compared with untreated control when the 
last dose of Em was applied (day 18). Columns, mean; bars, SEM. Tumor number (n) in each group is shown. ***, 
P<0.001. C, relative body weight was expressed as the ratio of body weight at various times after treatment com-
pared with the first day of treatment (day 0). Data are mean ± SEM (n=9). Only minus SD bars are shown to simplify 
the figure. A threshold of “0.85” is set as a solid line to evaluate body weight loss. D, Kaplan-Meier analysis on tumor 
volume doubling time. The median tumor volume doubling time of each group is depicted numerically. ***, P<0.001 
vs. IR (Mantel-Cox test). Tumor numbers (n) in each group are described in B. 
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provides an example of certain cancer types 
that may respond to embelin and radiotherapy 
as long as S-phase arrest can be achieved by 
embelin in those settings. We are currently de-
lineating the action mode of S-phase arrest to 
interpret the potential mechanism of embelin-
mediated radiosensitization.  
 
In conclusion, our results demonstrate that em-
belin significantly augments the anti-tumor ac-
tivity of ionizing radiation both in vitro and in 
vivo, therefore reveals an encouraging observa-
Figure 10. Immunohistochemical and molecular analysis of tumor tissues. A, tumor tissues were processed by anti-
Ki67, anti-PCNA, TUNEL, anti-mouse CD31 and H&E staining. Original magnification, x400. B, positive stained cells or 
microvessels were quantified by counting 8 random fields. Data are presented as a percentage (for Ki67 and PCNA) 
or an absolute counting (for TUNEL and CD31) per field (Original magnification, x200). Columns, mean; bars, SEM 
(n=8).  *, P< 0.05; ***, P< 0.001 vs. IR. C, whole cell lysates (50 μg) of tumor tissues were probed with anti-PARP 
and anti-XIAP antibody. GAPDH was used as a loading control.  
Radiosensitization of prostate cancer by embelin 
 
 
141                                                                                                            Am J Cancer Res 2011;1(2):128-143 
tion that corroborating the natural small-
molecule anti-apoptotic agent and conventional 
radiation therapy will result in enhanced effi-
cacy. The current study supports that embelin 
represents a promising adjuvant intervention 
that can improve the outcome of radiotherapy 
for hormone refractory prostate cancer that are 
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